Genetics of melanocytic nevi

Pigment Cell and Melanoma Research

Volumn 28, Issue 6, 2015, Pages 661-672

  Roh, Mi Ryung ^a,b   Eliades, Philip ^a,c   Gupta, Sameer ^a   Tsao, Hensin ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acquired melanocytic nevi; Blue nevi; Congenital melanocytic nevi; Genetics; Spitz nevi

Indexed keywords

B RAF KINASE;

ACQUIRED MELANOCYTIC NEVI; BLUE NEVUS; DYSPLASTIC NEVUS; GENE FREQUENCY; GENE REARRANGEMENT; GENETICS; HUMAN; JUVENILE MELANOMA; MALIGNANT TRANSFORMATION; MELANOMA; MELANOMAGENESIS; MOLECULAR PATHOLOGY; ONCOGENE H RAS; ONCOGENE N RAS; PIGMENTED NEVUS; REVIEW; SKIN CARCINOGENESIS; SOMATIC MUTATION; CARCINOGENESIS; GENETIC PREDISPOSITION; NEVUS, PIGMENTED; SKIN TUMOR;

CARCINOGENESIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEVUS, PIGMENTED; SKIN NEOPLASMS;

EID: 84944461022     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12412     Document Type: Review

References (120)

1. Argenziano, G., Zalaudek, I., Ferrara, G., Hofmann-Wellenhof, R., and Soyer, H.P. (2007). Proposal of a new classification system for melanocytic naevi. Br. J. Dermatol. 157, 217-227.
2. Barbacid, M. (1987). ras genes. Annu. Rev. Biochem. 56, 779-827.
3. Bastian, B.C., Wesselmann, U., Pinkel, D., and Leboit, P.E. (1999). Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma. J. Invest. Dermatol. 113, 1065-1069.
4. Bastian, B.C., LeBoit, P.E., and Pinkel, D. (2000). Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am. J. Pathol. 157, 967-972.
5. Bataille, V. (2003). Genetic epidemiology of melanoma. Eur. J. Cancer 39, 1341-1347.
6. Bataille, V., Bishop, J.A., Sasieni, P., Swerdlow, A.J., Pinney, E., Griffiths, K., and Cuzick, J. (1996). Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br. J. Cancer 73, 1605-1611.
7. Bauer, J., and Garbe, C. (2003). Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. Pigment Cell Res. 16, 297-306.
8. Bauer, J., Curtin, J.A., Pinkel, D., and Bastian, B.C. (2007). Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J. Invest. Dermatol. 127, 179-182.
9. Bender, R.P., McGinniss, M.J., Esmay, P., Velazquez, E.F., and Reimann, J.D. (2013). Identification of HRAS mutations and absence of GNAQ or GNA11 mutations in deep penetrating nevi. Mod. Pathol., 26, 1320-1328.
10. Bennett, D.C. (2003). Human melanocyte senescence and melanoma susceptibility genes. Oncogene 22, 3063-3069.
11. Bloethner, S., Snellman, E., Bermejo, J.L., Hiripi, E., Gast, A., Thirumaran, R.K., Wellenreuther, R., Hemminki, K., and Kumar, R. (2007). Differential gene expression in melanocytic nevi with the V600E BRAF mutation. Genes Chromosom. Cancer 46, 1019-1027.
12. Bogdan, I., Smolle, J., Kerl, H., Burg, G., and Boni, R. (2003). Melanoma ex naevo: a study of the associated naevus. Melanoma Res. 13, 213-217.
13. Cancer Genome Atlas Network. Electronic address, i.m.o., and Cancer Genome Atlas, N. (2015). Genomic classification of cutaneous melanoma. Cell, 161, 1681-1696.
14. Carr, J., and Mackie, R.M. (1994). Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br. J. Dermatol. 131, 72-77.
15. Charbel, C., Fontaine, R.H., Malouf, G.G. et al. (2014). NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi. J. Invest. Dermatol. 134, 1067-1074.
16. Charbel, C., Fontaine, R.H., Kadlub, N. et al. (2015). Clonogenic cell subpopulations maintain congenital melanocytic nevi. J. Invest. Dermatol. 135, 824-833.
17. Clark, W.H., Jr, Reimer, R.R., Greene, M., Ainsworth, A.M., and Mastrangelo, M.J. (1978). Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch. Dermatol., 114, 732-738.
18. Clark, W.H., Jr, Elder, D.E., Guerry, D.t., Epstein, M.N., Greene, M.H., and Van Horn, M. (1984). A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum. Pathol., 15, 1147-1165.
19. Clemmensen, O.J., and Kroon, S. (1988). The histology of "congenital features" in early acquired melanocytic nevi. J. Am. Acad. Dermatol. 19, 742-746.
20. Cribier, B.J., Santinelli, F., and Grosshans, E. (1999). Lack of clinical-pathological correlation in the diagnosis of congenital naevi. Br. J. Dermatol. 141, 1004-1009.
21. Da Forno, P.D., Pringle, J.H., Fletcher, A., Bamford, M., Su, L., Potter, L., and Saldanha, G. (2009). BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance. Br. J. Dermatol. 161, 364-372.
22. Dadzie, O.E., Yang, S., Emley, A., Keady, M., Bhawan, J., and Mahalingam, M. (2009). RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis. Br. J. Dermatol. 160, 368-375.
23. Dalle, S., Poulalhon, N., and Thomas, L. (2011). Vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med., 365, 1448-1449; author reply 1450.
24. Damsky, W.E., Theodosakis, N., and Bosenberg, M. (2014). Melanoma metastasis: new concepts and evolving paradigms. Oncogene 33, 2413-2422.
25. Damsky, W., Micevic, G., Meeth, K. et al. (2015). mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell 27, 41-56.
26. Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky, W.E. Jr, You, M.J., DePinho, R.A., McMahon, M., and Bosenberg, M. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544-552.
27. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
28. De Raeve, L.E., Claes, A., Ruiter, D.J., van Muijen, G.N., Roseeuw, D., and van Kempen, L.C. (2006). Distinct phenotypic changes between the superficial and deep component of giant congenital melanocytic naevi: a rationale for curettage. Br. J. Dermatol. 154, 485-492.
29. Demunter, A., Stas, M., Degreef, H., De Wolf-Peeters, C., and van den Oord, J.J. (2001). Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J. Invest. Dermatol. 117, 1483-1489.
30. Dessars, B., De Raeve, L.E., Morandini, R. et al. (2009). Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis. J. Invest. Dermatol. 129, 139-147.
31. Dhawan, P., Singh, A.B., Ellis, D.L., and Richmond, A. (2002). Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res. 62, 7335-7342.
32. Dhomen, N., Reis-Filho, J.S., da Rocha Dias, S., Hayward, R., Savage, K., Delmas, V., Larue, L., Pritchard, C., and Marais, R. (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15, 294-303.
33. van Dijk, M.C., Bernsen, M.R., and Ruiter, D.J. (2005). Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma. Am. J. Surg. Pathol. 29, 1145-1151.
34. Dimri, G.P., Testori, A., Acosta, M., and Campisi, J. (1996). Replicative senescence, aging and growth-regulatory transcription factors. Biol. Signals 5, 154-162.
35. Dong, J., Phelps, R.G., Qiao, R., Yao, S., Benard, O., Ronai, Z., and Aaronson, S.A. (2003). BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 63, 3883-3885.
36. van Elsas, A., Zerp, S.F., van der Flier, S., Kruse, K.M., Aarnoudse, C., Hayward, N.K., Ruiter, D.J., and Schrier, P.I. (1996). Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am. J. Pathol. 149, 883-893.
37. Emley, A., Yang, S., Wajapeyee, N., Green, M.R., and Mahalingam, M. (2010). Oncogenic BRAF and the tumor suppressor IGFBP7 in the genesis of atypical spitzoid nevomelanocytic proliferations. J. Cutan. Pathol. 37, 344-349.
38. Emley, A., Nguyen, L.P., Yang, S., and Mahalingam, M. (2011). Somatic mutations in GNAQ in amelanotic/hypomelanotic blue nevi. Hum. Pathol. 42, 136-140.
39. van Engen-van Grunsven, A.C., van Dijk, M.C., Ruiter, D.J., Klaasen, A., Mooi, W.J., and Blokx, W.A. (2010). HRAS-mutated Spitz tumors: a subtype of Spitz tumors with distinct features. Am. J. Surg. Pathol. 34, 1436-1441.
40. Fullen, D.R., Poynter, J.N., Lowe, L., Su, L.D., Elder, J.T., Nair, R.P., Johnson, T.M., and Gruber, S.B. (2006). BRAF and NRAS mutations in spitzoid melanocytic lesions. Mod. Pathol., 19, 1324-1332.
41. Gill, M., Renwick, N., Silvers, D.N., and Celebi, J.T. (2004). Lack of BRAF mutations in Spitz nevi. J. Invest. Dermatol. 122, 1325-1326.
42. Goel, V.K., Ibrahim, N., Jiang, G., Singhal, M., Fee, S., Flotte, T., Westmoreland, S., Haluska, F.S., Hinds, P.W., and Haluska, F.G. (2009). Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene 28, 2289-2298.
43. Gonzalez-Campora, R., Galera-Davidson, H., Vazquez-Ramirez, F.J., and Diaz-Cano, S. (1994). Blue nevus: classical types and new related entities. A differential diagnostic review. Pathol. Res. Pract. 190, 627-635.
44. Gray-Schopfer, V.C., Cheong, S.C., Chong, H., Chow, J., Moss, T., Abdel-Malek, Z.A., Marais, R., Wynford-Thomas, D., and Bennett, D.C. (2006). Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer 95, 496-505.
45. Haenssle, H.A., Kraus, S.L., Brehmer, F., Kretschmer, L., Volker, B., Asper, H., Kapp, A., and Gutzmer, R. (2012). Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. Arch. Dermatol. 148, 1183-1185.
46. Hafner, C., Stoehr, R., van Oers, J.M., Zwarthoff, E.C., Hofstaedter, F., Klein, C., Landthaler, M., Hartmann, A., and Vogt, T. (2009). The absence of BRAF, FGFR3, and PIK3CA mutations differentiates lentigo simplex from melanocytic nevus and solar lentigo. J. Invest. Dermatol. 129, 2730-2735.
47. Hastrup, N., Osterlind, A., Drzewiecki, K.T., and Hou-Jensen, K. (1991). The presence of dysplastic nevus remnants in malignant melanomas. A population-based study of 551 malignant melanomas. Am. J. Dermatopathol. 13, 378-385.
48. Hatzivassiliou, G., Song, K., Yen, I. et al. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435.
49. Held, L., Eigentler, T.K., Metzler, G., Leiter, U., Messina, J.L., Glass, L.F., Garbe, C., and Bauer, J. (2013). Proliferative activity, chromosomal aberrations, and tumor-specific mutations in the differential diagnosis between blue nevi and melanoma. Am. J. Pathol. 182, 640-645.
50. Ichii-Nakato, N., Takata, M., Takayanagi, S., Takashima, S., Lin, J., Murata, H., Fujimoto, A., Hatta, N., and Saida, T. (2006). High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. J. Invest. Dermatol. 126, 2111-2118.
51. Jafari, M., Papp, T., Kirchner, S., Diener, U., Henschler, D., Burg, G., and Schiffmann, D. (1995). Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J. Cancer Res. Clin. Oncol. 121, 23-30.
52. Jensen, D.E., and Rauscher, F.J. 3rd (1999). BAP1, a candidate tumor suppressor protein that interacts with BRCA1. Ann. N. Y. Acad. Sci. 886, 191-194.
53. Jensen, D.E., Proctor, M., Marquis, S.T. et al. (1998). BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16, 1097-1112.
54. Jiveskog, S., Ragnarsson-Olding, B., Platz, A., and Ringborg, U. (1998). N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J. Invest. Dermatol. 111, 757-761.
55. Karram, S., Novy, M., Saroufim, M., Loya, A., Taraif, S., Houreih, M.A., Rauscher, B., Habib, R.H., Oberkanins, C., and Khalifeh, I. (2013). Predictors of BRAF mutation in melanocytic nevi: analysis across regions with different UV radiation exposure. Am. J. Dermatopathol. 35, 412-418.
56. Kinsler, V.A., Thomas, A.C., Ishida, M. et al. (2013). Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J. Invest. Dermatol. 133, 2229-2236.
57. Krengel, S., Hauschild, A., and Schafer, T. (2006). Melanoma risk in congenital melanocytic naevi: a systematic review. Br. J. Dermatol. 155, 1-8.
58. Kuwata, T., Kitagawa, M., and Kasuga, T. (1993). Proliferative activity of primary cutaneous melanocytic tumours. Virchows Arch. A. Pathol. Anat. Histopathol. 423, 359-364.
59. La Porta, C.A., Cardano, R., Facchetti, F., Presicce, P., Rao, S., Privitera, E., Clemente, C., and Mihm, M.C. Jr (2006). BRAF V599E mutation occurs in Spitz and Reed naevi. J. Eur. Acad. Dermatol. Venereol. 20, 1164-1165.
60. Leopold, J.G., and Richards, D.B. (1968). The interrelationship of blue and common naevi. Indian J. Pathol. Bacteriol. 95, 37-46.
61. Lin, W.M., Luo, S., Muzikansky, A., Lobo, A.Z., Tanabe, K.K., Sober, A.J., Cosimi, A.B., Tsao, H., and Duncan, L.M. (2015). Outcome of patients with de novo versus nevus-associated melanoma. J. Am. Acad. Dermatol. 72, 54-58.
62. Magana-Garcia, M., and Ackerman, A.B. (1990). What are nevus cells? Am. J. Dermatopathol. 12, 93-102.
63. Maldonado, J.L., Timmerman, L., Fridlyand, J., and Bastian, B.C. (2004). Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway. Am. J. Pathol. 164, 1783-1787.
64. Marchetti, M.A., Kiuru, M.H., Busam, K.J., Marghoob, A.A., Scope, A., Dusza, S.W., Cordova, M.A., Fonseca, M., Wu, X., and Halpern, A.C. (2014). Melanocytic naevi with globular and reticular dermoscopic patterns display distinct BRAF V600E expression profiles and histopathological patterns. Br. J. Dermatol. 171, 1060-1065.
65. Marghoob, A.A., Kopf, A.W., Rigel, D.S., Bart, R.S., Friedman, R.J., Yadav, S., Abadir, M., Sanfilippo, L., Silverman, M.K., and Vossaert, K.A. (1994). Risk of cutaneous malignant melanoma in patients with 'classic' atypical-mole syndrome. A case-control study. Arch. Dermatol. 130, 993-998.
66. McClenahan, P., Lin, L.L., Tan, J.M. et al. (2014). BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib. JAMA Dermatol. 150, 1079-1082.
67. Michaloglou, C., Vredeveld, L.C., Mooi, W.J., and Peeper, D.S. (2008). BRAF(E600) in benign and malignant human tumours. Oncogene 27, 877-895.
68. Mihic-Probst, D., Perren, A., Schmid, S., Saremaslani, P., Komminoth, P., and Heitz, P.U. (2004). Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma. Anticancer Res. 24, 2415-2418.
69. Miracco, C., Margherita De Santi, M., Schurfeld, K. et al. (2002). Quantitative in situ evaluation of telomeres in fluorescence in situ hybridization-processed sections of cutaneous melanocytic lesions and correlation with telomerase activity. Br. J. Dermatol. 146, 399-408.
70. Mooi, W.J., and Peeper, D.S. (2006). Oncogene-induced cell senescence-halting on the road to cancer. N. Engl. J. Med. 355, 1037-1046.
71. Murali, R., McCarthy, S.W., and Scolyer, R.A. (2009). Blue nevi and related lesions: a review highlighting atypical and newly described variants, distinguishing features and diagnostic pitfalls. Adv. Anat. Pathol. 16, 365-382.
72. Nasti, T.H., Cochran, J.B., Tsuruta, Y., Yusuf, N., McKay, K.M., Athar, M., Timares, L., and Elmets, C.A. (2015). A murine model for the development of melanocytic nevi and their progression to melanoma. Mol. Carcinog. doi: 10.1002/mc.22310. [Epub ahead of print].
73. Palmedo, G., Hantschke, M., Rutten, A., Mentzel, T., Hugel, H., Flaig, M.J., Yazdi, A.S., Sander, C.A., and Kutzner, H. (2004). The T1796A mutation of the BRAF gene is absent in Spitz nevi. J. Cutan. Pathol. 31, 266-270.
74. Papp, T., Pemsel, H., Zimmermann, R., Bastrop, R., Weiss, D.G., and Schiffmann, D. (1999). Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J. Med. Genet. 36, 610-614.
75. Papp, T., Pemsel, H., Rollwitz, I., Schipper, H., Weiss, D.G., Schiffmann, D., and Zimmermann, R. (2003). Mutational analysis of N-ras, p53, CDKN2A (p16(INK4a)), p14(ARF), CDK4, and MC1R genes in human dysplastic melanocytic naevi. J. Med. Genet. 40, E14.
76. Papp, T., Schipper, H., Kumar, K., Schiffmann, D., and Zimmermann, R. (2005). Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi. Melanoma Res. 15, 401-407.
77. Patton, E.E., Widlund, H.R., Kutok, J.L. et al. (2005). BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr. Biol. 15, 249-254.
78. Perier-Muzet, M., Thomas, L., Poulalhon, N., Debarbieux, S., Bringuier, P.P., Duru, G., Depaepe, L., Balme, B., and Dalle, S. (2014). Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. J. Invest. Dermatol. 134, 1351-1358.
79. Phadke, P.A., Rakheja, D., Le, L.P., Selim, M.A., Kapur, P., Davis, A., Mihm, M.C. Jr, and Hoang, M.P. (2011). Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases. Am. J. Surg. Pathol. 35, 656-669.
80. Pollock, P.M., Harper, U.L., Hansen, K.S. et al. (2003). High frequency of BRAF mutations in nevi. Nat. Genet. 33, 19-20.
81. Poynter, J.N., Elder, J.T., Fullen, D.R., Nair, R.P., Soengas, M.S., Johnson, T.M., Redman, B., Thomas, N.E., and Gruber, S.B. (2006). BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res. 16, 267-273.
82. Pozzobon, F.C., Puig-Butille, J.A., Gonzalez-Alvarez, T., Carrera, C., Aguilera, P., Alos, L., Badenas, C., Grichnik, J.M., Malvehy, J., and Puig, S. (2014). Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma. Br. J. Dermatol. 171, 754-759.
83. Qi, R.Q., He, L., Zheng, S. et al. (2011). BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han. J. Invest. Dermatol. 131, 1129-1138.
84. Rhodes, A.R., Sober, A.J., Day, C.L., Melski, J.W., Harrist, T.J., Mihm, M.C. Jr, and Fitzpatrick, T.B. (1982). The malignant potential of small congenital nevocellular nevi. An estimate of association based on a histologic study of 234 primary cutaneous melanomas. J. Am. Acad. Dermatol. 6, 230-241.
85. Rhodes, A.R., Harrist, T.J., Day, C.L., Mihm, M.C. Jr, Fitzpatrick, T.B., and Sober, A.J. (1983). Dysplastic melanocytic nevi in histologic association with 234 primary cutaneous melanomas. J. Am. Acad. Dermatol. 9, 563-574.
86. Rhodes, A.R., Silverman, R.A., Harrist, T.J., and Melski, J.W. (1985). A histologic comparison of congenital and acquired nevomelanocytic nevi. Arch. Dermatol. 121, 1266-1273.
87. Rivers, J.K. (2004). Is there more than one road to melanoma? Lancet 363, 728-730.
88. Ross, A.L., Sanchez, M.I., and Grichnik, J.M. (2011). Molecular nevogenesis. Dermatol. Res. Pract. 2011, 463184.
89. Saldanha, G., Purnell, D., Fletcher, A., Potter, L., Gillies, A., and Pringle, J.H. (2004). High BRAF mutation frequency does not characterize all melanocytic tumor types. International journal of cancer. Int. J. Cancer 111, 705-710.
90. Saroufim, M., Novy, M., Taraif, S., Habib, R.H., Loya, A., Rauscher, B., Kriegshauser, G., Oberkanins, C., and Khalifeh, I. (2014). BRAF mutational epidemiology in dysplastic nevi: does different solar UV radiation exposure matter? J. Eur. Acad. Dermatol. Venereol. 28, 615-625.
91. van Schanke, A., van Venrooij, G.M., Jongsma, M.J., Banus, H.A., Mullenders, L.H., van Kranen, H.J., and de Gruijl, F.R. (2006). Induction of nevi and skin tumors in Ink4a/Arf Xpa knockout mice by neonatal, intermittent, or chronic UVB exposures. Cancer Res. 66, 2608-2615.
92. Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602.
93. Seykora, J., and Elder, D. (1996). Dysplastic nevi and other risk markers for melanoma. Semin. Oncol. 23, 682-687.
94. Shakhova, O., Zingg, D., Schaefer, S.M. et al. (2012). Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat. Cell Biol. 14, 882-890.
95. Sober, A.J., and Burstein, J.M. (1995). Precursors to skin cancer. Cancer 75, 645-650.
96. Takata, M., Lin, J., Takayanagi, S., Suzuki, T., Ansai, S., Kimura, T., Cerroni, L., and Saida, T. (2007). Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion. Br. J. Dermatol. 156, 1287-1294.
97. Tan, J.M., Lin, L.L., Lambie, D., Flewell-Smith, R., Jagirdar, K., Schaider, H., Sturm, R.A., Prow, T.W., and Soyer, H.P. (2015). BRAF wild-type melanoma in situ arising in a BRAF V600E mutant dysplastic nevus. JAMA Dermatol. 151, 417-421.
98. Temple-Camp, C.R., Saxe, N., and King, H. (1988). Benign and malignant cellular blue nevus. A clinicopathological study of 30 cases. Am. J. Dermatopathol. 10, 289-296.
99. Tschandl, P., Berghoff, A.S., Preusser, M., Burgstaller-Muehlbacher, S., Pehamberger, H., Okamoto, I., and Kittler, H. (2013). NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi. PLoS ONE 8, e69639.
100. Turner, D.J., Zirvi, M.A., Barany, F., Elenitsas, R., and Seykora, J. (2005). Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction. J. Cutan. Pathol. 32, 334-339.
101. Uribe, P., Wistuba, I.I., and Gonzalez, S. (2003). BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am. J. Dermatopathol. 25, 365-370.
102. Uribe, P., Andrade, L., and Gonzalez, S. (2006). Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J. Invest. Dermatol. 126, 161-166.
103. Van Raamsdonk, C.D., Fitch, K.R., Fuchs, H., de Angelis, M.H., and Barsh, G.S. (2004). Effects of G-protein mutations on skin color. Nat. Genet. 36, 961-968.
104. Van Raamsdonk, C.D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O'Brien, J.M., Simpson, E.M., Barsh, G.S., and Bastian, B.C. (2009). Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457, 599-602.
105. Van Raamsdonk, C.D., Griewank, K.G., Crosby, M.B. et al. (2010). Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 363, 2191-2199.
106. Venesio, T., Chiorino, G., Balsamo, A., Zaccagna, A., Petti, C., Scatolini, M., Pisacane, A., Sarotto, I., Picciotto, F., and Risio, M. (2008). In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation. Mod. Pathol., 21, 716-726.
107. Viros, A., Fridlyand, J., Bauer, J., Lasithiotakis, K., Garbe, C., Pinkel, D., and Bastian, B.C. (2008). Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 5, e120.
108. Vredeveld, L.C., Possik, P.A., Smit, M.A. et al. (2012). Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 26, 1055-1069.
109. Watt, A.J., Kotsis, S.V., and Chung, K.C. (2004). Risk of melanoma arising in large congenital melanocytic nevi: a systematic review. Plast. Reconstr. Surg. 113, 1968-1974.
110. Wiesner, T., Obenauf, A.C., Murali, R. et al. (2011). Germline mutations in BAP1 predispose to melanocytic tumors. Nat. Genet. 43, 1018-1021.
111. Wiesner, T., Murali, R., Fried, I., Cerroni, L., Busam, K., Kutzner, H., and Bastian, B.C. (2012). A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am. J. Surg. Pathol. 36, 818-830.
112. Wiesner, T., He, J., Yelensky, R. et al. (2014). Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat. Commun. 5, 3116.
113. Wu, J., Rosenbaum, E., Begum, S., and Westra, W.H. (2007). Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. Am. J. Dermatopathol. 29, 534-537.
114. Wu, D., Wang, M., Wang, X., Yin, N., Song, T., Li, H., Yu, J., Wang, D.M., and Zhao, Z. (2011). Lack of BRAF(V600E) mutations in giant congenital melanocytic nevi in a Chinese population. Am. J. Dermatopathol. 33, 341-344.
115. Yadav, S., Vossaert, K.A., Kopf, A.W., Silverman, M., and Grin-Jorgensen, C. (1993). Histopathologic correlates of structures seen on dermoscopy (epiluminescence microscopy). Am. J. Dermatopathol. 15, 297-305.
116. Yan, J., Roy, S., Apolloni, A., Lane, A., and Hancock, J.F. (1998). Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J. Biol. Chem. 273, 24052-24056.
117. Yazdi, A.S., Palmedo, G., Flaig, M.J. et al. (2003). Mutations of the BRAF gene in benign and malignant melanocytic lesions. J. Invest. Dermatol. 121, 1160-1162.
118. Zembowicz, A., and Mihm, M.C. (2004). Dermal dendritic melanocytic proliferations: an update. Histopathology 45, 433-451.
119. Zembowicz, A., and Phadke, P.A. (2011). Blue nevi and variants: an update. Arch. Pathol. Lab. Med. 135, 327-336.
120. Zimmermann, A.A., and Cornbleet, T. (1948). The development of epidermal pigmentation in the Negro fetus. J. Invest. Dermatol. 11, 383-395.